Flecainide against fetal supraventricular tachycardia complicated by hydrops fetalis. 1998

P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
Department of Obstetrics and Gynecology, University Hospital of Caen, France.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011256 Pregnancy Outcome Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO. Outcome, Pregnancy,Outcomes, Pregnancy,Pregnancy Outcomes
D005260 Female Females
D005315 Fetal Diseases Pathophysiological conditions of the FETUS in the UTERUS. Some fetal diseases may be treated with FETAL THERAPIES. Embryopathies,Disease, Fetal,Diseases, Fetal,Embryopathy,Fetal Disease
D005424 Flecainide A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS. Flecainide Acetate,Apocard,Flecadura,Flecainid-Isis,Flecainide Monoacetate,Flecainide Monoacetate, (+-)-Isomer,Flecainide Monoacetate, (R)-Isomer,Flecainide Monoacetate, (S)-Isomer,Flecainide, (R)-Isomer,Flecainide, (S)-Isomer,Flecainide, 5-HO-N-(6-oxo)-Derivative,Flecainide, 5-HO-N-(6-oxo)-Derivative, (+-)-Isomer,Flecatab,Flécaïne,R818,Tambocor,Flecainid Isis
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D013617 Tachycardia, Supraventricular A generic expression for any tachycardia that originates above the BUNDLE OF HIS. Supraventricular Tachycardia,Supraventricular Tachycardias,Tachycardias, Supraventricular
D015160 Hydrops Fetalis Abnormal accumulation of serous fluid in two or more fetal compartments, such as SKIN; PLEURA; PERICARDIUM; PLACENTA; PERITONEUM; AMNIOTIC FLUID. General fetal EDEMA may be of non-immunologic origin, or of immunologic origin as in the case of ERYTHROBLASTOSIS FETALIS. Edema, Fetal,Fetal Edema,Fetal Hydrops,Familial Non-Immune Hydrops Fetalis,Hydrops Fetalis Nonimmune,Hydrops Fetalis, Idiopathic,Hydrops Fetalis, Immune,Hydrops Fetalis, Non-Immune,Hydrops Fetalis, Nonimmune,Idiopathic Hydrops Fetalis,Immune Hydrops Fetalis,Non-Immune Hydrops Fetalis,Familial Non Immune Hydrops Fetalis,Fetali, Idiopathic Hydrops,Fetalis Nonimmune, Hydrops,Fetalis Nonimmunes, Hydrops,Fetalis, Idiopathic Hydrops,Hydrops Fetali, Idiopathic,Hydrops Fetali, Nonimmune,Hydrops Fetalis Nonimmunes,Hydrops, Fetal,Idiopathic Hydrops Fetali,Nonimmune Hydrops Fetali,Nonimmune Hydrops Fetalis,Nonimmune, Hydrops Fetalis,Nonimmunes, Hydrops Fetalis

Related Publications

P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
January 2022, Case reports in obstetrics and gynecology,
P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
November 1996, American journal of perinatology,
P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
January 2003, Fetal diagnosis and therapy,
P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
September 2014, Turkish journal of obstetrics and gynecology,
P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
July 2006, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology,
P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
September 1991, Obstetrics and gynecology,
P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
January 1985, Gynecologic and obstetric investigation,
P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
February 1986, European journal of pediatrics,
P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
September 1985, Clinical pediatrics,
P Barjot, and P Hamel, and P Calmelet, and P Maragnes, and M Herlicoviez
August 1994, Arquivos brasileiros de cardiologia,
Copied contents to your clipboard!